In a previous report, we showed that PAM50 HER2-enriched tumours have a higher pCR rate compared to PAM50 non-HER2-enriched tumours (45.5% vs 13.8%: odds ratio [OR] = 5.21, 95% confidence interval [CI] 1.1–27.6, p = 0.042, multivariable logistic regression model).8, 9, 10, 11, 12, 13, 14 In this 40-patient subpopulation with ESD, the PAM50 subtype distribution was 2.5% (1/40) Basal-like, 27.5% (11/40) HER2-enriched, 25% (10/40) Luminal A, 37.5% (15/40) Luminal B and 7.5% (3/40) Normal-like. Here, ERBB2 is linked to neoplasm.